Stock LEXICON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Lexicon Pharmaceuticals, Inc. Nasdaq

Equities

US5288721047

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sector Update: Health Care Stocks Gain in Late Afternoon
MT
Lexicon Pharmaceuticals Resubmits New Drug Application for Potential Type 1 Diabetes Therapy
MT
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
AQ
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
CI
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
AQ
Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
CI
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
AQ
HC Wainwright Initiates Lexicon Pharmaceuticals With Buy Rating, $10 Price Target
MT
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
AQ
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
AQ
Transcript : Lexicon Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell
MT
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
AQ
Lexicon Pharmaceuticals, Inc. Announces A New Post-Hoc Analysis of Clinical Data Showing That Inpefa® (Sotagliflozin), A Dual Oral Inhibitor of Sglt2 and Sglt1, Reduced the Risk of Heart Failure-Related Events Across A Diverse Population of Patients, Including Patients with Preserved Ejection Fraction
CI
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
AQ
Lexicon: Q1 Earnings Snapshot
AQ
Transcript : Lexicon Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M
MT
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. Stock
  5. News Lexicon Pharmaceuticals, Inc.